advanced search

OCULAR

USER TESTING: CRITICAL FOR TRULY UNDERSTANDING PATIENT NEEDS
OCULAR
Fanny Sellier
Nemera
USER TESTING: CRITICAL FOR TRULY UNDERSTANDING PATIENT NEEDS
Fanny Sellier presents a trio of comparative user studies between Nemera’s Novelia® preservative-free, multidose eyedropper and similar products from competitors
ACCURATE, PRECISE MICROLITRE DOSING WITH PREFILLABLE SYRINGES FOR OPHTHALMIC INJECTIONS
OCULAR
Dr Gautam N Shetty
Congruence Medical Solutions
ACCURATE, PRECISE MICROLITRE DOSING WITH PREFILLABLE SYRINGES FOR OPHTHALMIC INJECTIONS
Gautam Shetty discusses the challenges inherent to delivering microlitre dosage volumes accurately from a standard prefilled syringe, and introduces Congruence’s Microlitre Dosing Syringe (MDS) platform as a solution.
BREAKING THE VICIOUS CIRCLE OF DRY EYE DISEASE
OCULAR
Dr Christian Roesky
BREAKING THE VICIOUS CIRCLE OF DRY EYE DISEASE
Christian Roesky discusses the underserved condition of dry eye disease, and presents two products in Novaliq’s pipelinefor the treatment of different types of DED.
KEEPING PRESERVATIVE-FREE EYEDROPS STERILE WITH THE STERIDROP™ TUBE
OCULAR
Ralf Künzi
KEEPING PRESERVATIVE-FREE EYEDROPS STERILE WITH THE STERIDROP™ TUBE
Ralf Künzi introduces the SteriDrop™ tube – a new multidose eyedrop delivery solution made in collaboration with Aptar Pharma.
THE CHALLENGES AND OPPORTUNITIES OF DRUG DELIVERY THROUGH A COMPLEX BARRIER
OCULAR
Dr Jon Volmer
MedPharm
THE CHALLENGES AND OPPORTUNITIES OF DRUG DELIVERY THROUGH A COMPLEX BARRIER
Jon Volmer, Marc Brown and Jeremy Drummond discuss the development and use of advanced ex vivo and in vitro models for testing new ocular medicines to meet a growing unmet need.
TARGETING DRUGS TO DISEASED OCULAR CELLS
EARLY INSIGHT
Frazer P Coutinho
TARGETING DRUGS TO DISEASED OCULAR CELLS
Frazer Coutinho, Colin Green and Ilva Rupenthal discuss the targeted delivery of ocular therapeutics to diseased cells, using the cell-penetrating peptide, Xentry.
INTRAVITREAL INJECTION OF VEGF INHIBITORS – IMPACT OF DRUG CONTAINERS
EXPERT VIEW
Douglas Cusato
INTRAVITREAL INJECTION OF VEGF INHIBITORS – IMPACT OF DRUG CONTAINERS
With the increasing use of intravitreal injections of vascular endothelial growth factor inhibitors in the treatment of numerous serious ocular diseases, Douglas Cusato provides a detailed comparative analysis of the issues at play.
ACUSTREAM™: BRINGING TOPICAL OPHTHALMIC DRUG DELIVERY INTO THE MODERN ERA
OCULAR
Dr Peter Noymer
ACUSTREAM™: BRINGING TOPICAL OPHTHALMIC DRUG DELIVERY INTO THE MODERN ERA
Peter Noymer, Ehud Ivri, Reynaldo Quintana and Mark Blumenkranz introduce AcuStream, a novel device for next-generation delivery of topical ophthalmic delivery via an aim-assisted stream.
TRENDS IN ANTI-GLAUCOMA TOPICAL TREATMENTS
OCULAR
Rouven Kraus
Aero Pump
TRENDS IN ANTI-GLAUCOMA TOPICAL TREATMENTS
Rouven Kraus presents the case for multidose delivery systems rather than single-use disposables, and introduces Aero Pump’s Ophthalmic Multidose System.
EXPANDING CONNECTIVITY: ADD-ONS FOR OPHTHALMIC AND NASAL DELIVERY
CONNECTIVITY
Nemera
EXPANDING CONNECTIVITY: ADD-ONS FOR OPHTHALMIC AND NASAL DELIVERY
Nemera introduces the e-Novelia® and e-Advancia® add-ons for ophthalmic and nasal devices.
AN OPTIMISED PLATFORM FOR HIGHLY SENSITIVE BIOLOGICS
PREFILLED SYRINGES
Alessio Bonati
Stevanato Group
AN OPTIMISED PLATFORM FOR HIGHLY SENSITIVE BIOLOGICS
Alessio Bonati discusses the problematic interactions between drugs and their primary containers and goes on to introduce the Alba platform, Ompi’s range of primary glass containers designed to unify drug-container interactions over a product’s lifecycle.
SUSTAINED DRUG DELIVERY TO THE POSTERIOR SEGMENTS OF THE EYE
OCULAR
Dr Shikha P Barman
SUSTAINED DRUG DELIVERY TO THE POSTERIOR SEGMENTS OF THE EYE
Shikha Barman reviews approaches for delivering drugs for diseases of the back of the eye, and introduces EySite-InjecT™.
FANNY SELLIER, NEMERA
INTERVIEW
Fanny Sellier
Nemera
FANNY SELLIER, NEMERA
Talking here with ONDrugDelivery Magazine, Ms Sellier discusses Nemera’s multidose eyedropper system Novelia® for preservative-free formulations. She explains how this platform has been developed to improve patients’ lives.
AQUEOUS-FREE OPHTHALMIC DELIVERY TECHNOLOGY
OCULAR
Dr Christian Roesky
AQUEOUS-FREE OPHTHALMIC DELIVERY TECHNOLOGY
Traditional aqueous vehicles for topical ophthalmic medications suffer from a number of limitations. Christian Roesky reviews the benefits of EyeSol®, a proprietary aqueous-free drug delivery technology.
PHYSICOCHEMICAL BIOEQUIVALENCE IN OPHTHALMIC MICROEMULSIONS
EXPERT VIEW
Dr Paul Kippax
PHYSICOCHEMICAL BIOEQUIVALENCE IN OPHTHALMIC MICROEMULSIONS
Here, Paul Kippax describes the methods by which bioequivalence can be established for ophthalmic microemulsions by in vitro testing, saving the need for costly clinical trials.
USING PHYSICAL FORCES TO ENHANCE OCULAR DRUG DELIVERY
EXPERT VIEW
Di Huang
USING PHYSICAL FORCES TO ENHANCE OCULAR DRUG DELIVERY
Di Huang, Erica Chen and Ilva Rupenthal discuss the possibilities offered by physical force-based methods of enhancing the efficacy of ophthalmic drug delivery by providing a way past the eye’s natural barriers.
SUSTAINED RELEASE OCULAR THERAPEUTICS
EXPERT VIEW
Michael O'Rourke
SUSTAINED RELEASE OCULAR THERAPEUTICS
Michael O’Rourke gives an overview of the current state of the ophthalmics market, going into greater detail on the opportunities offered in the area of sustained-release technologies and therapies.
BIODEGRADABLE IMPLANTS FOR SUSTAINED INTRAOCULAR DELIVERY
OCULAR
Dr Raj Thakur
BIODEGRADABLE IMPLANTS FOR SUSTAINED INTRAOCULAR DELIVERY
Raj Thakur and Prof David Jones discuss the difficulty of treating diseases of the back and front of the eye, and introduce a possible solution: OcuLief™ and EyeLief™, Re-Vana’s two proprietary sustained-release platforms.
CREATING SUSTAINABLE BIOTHERAPEUTICS FACTORIES IN THE EYE
OCULAR
Dr Patricia Zilliox
CREATING SUSTAINABLE BIOTHERAPEUTICS FACTORIES IN THE EYE
Patricia Zilliox discusses the inherent difficulties in drug delivery to the back of the eye and how this creates an unmet need in ophthalmology. Dr Zilliox goes on to describe Eyevensys’ novel solution to this problem, and the company’s first lead product, EYS606.
A TOPICAL OCULAR RING DESIGNED TO REPLACE GLAUCOMA EYE DROPS
OCULAR
Anne Brody Rubin
A TOPICAL OCULAR RING DESIGNED TO REPLACE GLAUCOMA EYE DROPS
Anne Brody Rubin introduces ForSight VISION5's ring-shaped ocular insert containing prostaglandin for the lowering of intra-ocular pressure in glaucoma.
OPSISPORIN: A LONG-ACTING DRUG DELIVERY APPROACH FOR UVEITIS
OCULAR
Dr Paul Seaman
OPSISPORIN: A LONG-ACTING DRUG DELIVERY APPROACH FOR UVEITIS
Here, Paul Seaman and Daniel Palmer discuss Midatech Pharma’s next generation treatments for auto-immune ocular diseases, which use a combination of innovative, sustained-release drug products.
NEW SOLUTIONS FOR OPHTHALMIC DRUG DELIVERY USING BIODEGRADABLE SILICA MATRIX
OCULAR
Dr Mika Jokinen
NEW SOLUTIONS FOR OPHTHALMIC DRUG DELIVERY USING BIODEGRADABLE SILICA MATRIX
Mika Jokinen, Cora Griffin, and Lasse Leino, PhD describe the novel opportunities that biodegradable silica matrix technology offers to ophthalmic drug delivery.
IMPROVING OPHTHALMIC DRUG DELIVERY WITH NOVEL EMULSION TECHNOLOGIES
OCULAR
Robin de Bruijn
IMPROVING OPHTHALMIC DRUG DELIVERY WITH NOVEL EMULSION TECHNOLOGIES
Robin de Bruijn and Frank de Jong describe EmulTech’s ET4ME micro-encapsulation process, and its suitability as a particle formation technology for enhancing and enabling ophthalmic injectables.
USING INTELLIGENT DESIGN TO DELIVER SAFE MULTI-DOSE EYE DROPS
OCULAR
Fanny Sellier
Nemera
USING INTELLIGENT DESIGN TO DELIVER SAFE MULTI-DOSE EYE DROPS
Ms Fanny Sellier, explains how the intelligent design of multi-dose bottles provides a viable means of delivering safe, preservative-free eye drops.
Top